title: Matrine alleviates early brain injury after experimental subarachnoid hemorrhage in rats: possible involvement of PI3K/Akt-mediated NF-κB inhibition and Keap1/Nrf2-dependent HO-1 inductionn.
abstract: Matrine is a quinolizidine alkaloid derived from the herb Radix Sophorae Flavescentis, and possesses anti-oxidant, anti-inflammatory and anti-tumoral properties. However, its effectiveness against subarachnoid hemorrhage (SAH) is not well known. In this study, we investigated the effects of matrine on early brain injury (EBI) and the related potential mechanisms following SAH in rats. Our results showed that matrine pretreatment partially alleviated SAH-induced EBI, including neurological deficit, severity of SAH grade, brain edema, and blood-brain barrier (BBB) disruption in rats. In addition, SAH procedure induced BBB disruption with concomitant upregulation of MMP-9 expression and downregulation of tight junction proteins expression of BBB, namely, ZO-1 and occludin, which was partially reversed by matrine pretreatment. Matrine also reduced the increased levels of inflammatory cytokines TNF-α and IL-1β after the SAH operation. SAH induced neural cell apoptosis, as demonstrated by high apoptotic index and increased expression of Bax and caspase-3 proteins, as well as the reduced Bcl-2 expression, which were reversed by matrine pretreatment. Furthermore, matrine pretreatment partially suppressed SAH-induced Akt phosphorylation and IκB-α phosphorylation and degradation, and reduced NF-kB P65 protein levels. The expression of Keap1, Nrf2, and HO-1 proteins was distinctly enhanced in the SAH+matrine group, compared with the SAH+vehicle groups. Matrine pretreatment suppressed SAH-induced MMP-9 expression, which could be partially blocked by HO-1 inhibitor Sn-protoporphyrin IX (SnPP IX) but promoted by phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002. Our results suggest that matrine may alleviate EBI after experimental subarachnoid hemorrhage in rats possibly via PI3K/Akt-mediated NF-κB inhibition and Keap1/Nrf2-dependent HO-1 induction.
authors.affiliation: The Ninth Hospital of Xi'an Department of Neurosurgery Xi'an China.
authors.forename: X
authors.initials: X
authors.lastname: Liu
authors.affiliation: The Ninth Hospital of Xi'an Department of Neurosurgery Xi'an China.
authors.forename: X
authors.initials: X
authors.lastname: Zhang
authors.affiliation: The Ninth Hospital of Xi'an Department of Neurosurgery Xi'an China.
authors.forename: K
authors.initials: K
authors.lastname: Ma
authors.affiliation: The Ninth Hospital of Xi'an Department of Neurosurgery Xi'an China.
authors.forename: R
authors.initials: R
authors.lastname: Zhang
authors.affiliation: The Ninth Hospital of Xi'an Department of Neurosurgery Xi'an China.
authors.forename: P
authors.initials: P
authors.lastname: Hou
authors.affiliation: The Ninth Hospital of Xi'an Department of Neurosurgery Xi'an China.
authors.forename: B
authors.initials: B
authors.lastname: Sun
authors.affiliation: The Ninth Hospital of Xi'an Department of Neurosurgery Xi'an China.
authors.forename: S
authors.initials: S
authors.lastname: Yuan
authors.affiliation: The Ninth Hospital of Xi'an Department of Neurosurgery Xi'an China.
authors.forename: Z
authors.initials: Z
authors.lastname: Wang
authors.affiliation: The Ninth Hospital of Xi'an Department of Neurosurgery Xi'an China zhanhuiliucl@tom.com.
authors.forename: Z
authors.initials: Z
authors.lastname: Liu
mesh_terms: D000470:Alkaloids / Q000494:pharmacology*; D000818:Animals; D001812:Blood-Brain Barrier / Q000378:metabolism; D001930:Brain Injuries / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D002867:Chromones / Q000494:pharmacology; D004195:Disease Models, Animal; D051547:Heme Oxygenase-1 / Q000378:metabolism*; D000072019:Kelch-Like ECH-Associated Protein 1 / Q000378:metabolism; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D009025:Morpholines / Q000494:pharmacology; D051267:NF-E2-Related Factor 2 / Q000378:metabolism; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D011807:Quinolizines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015398:Signal Transduction / Q000187:drug effects*; D013345:Subarachnoid Hemorrhage / Q000150:complications*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D000093842:Matrines
chemical_list: D000470:Alkaloids; D002867:Chromones; D051547:Heme Oxygenase-1; D000072019:Kelch-Like ECH-Associated Protein 1; D020780:Matrix Metalloproteinase 9; D009025:Morpholines; D051267:NF-E2-Related Factor 2; D016328:NF-kappa B; D018696:Neuroprotective Agents; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt; D019253:Proto-Oncogene Proteins c-bcl-2; D011807:Quinolizines; D014409:Tumor Necrosis Factor-alpha; D000093842:Matrines; C486610:KEAP1 protein, rat; C495637:Nfe2l2 protein, rat; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one